Cell line development & engineering Asia 2012(¼¼Æ÷ÁÖ °³¹ß ¹× ¿£Áö´Ï¾î¸µ ¾Æ½Ã¾Æ 2012) 2012³â 2¿ù 20-23ÀÏ, Áß±¹ »óÇÏÀÌ
Cell Line Development and Engineering Asia°¡ 2012³â 2¿ù 20ÀϺÎÅÍ 23ÀϱîÁö Áß±¹ »óÇÏÀÌ¿¡¼ °³Ãֵ˴ϴÙ. ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ¾÷°è, CMO, ¿¬±¸±â°ü Àü¹®°¡ ¹× °úÇÐÀÚ¿Í ÁÖ¿ä Å×Å©³î·ÎÁö ÇÁ·Î¹ÙÀÌ´õ°¡ ÇÑÀÚ¸®¿¡ ¸ðÀÔ´Ï´Ù. À̹ø Çà»ç¿¡¼´Â ºñ¿ë È¿À²ÀÌ ³ôÀº ¼¼Æ÷ÁÖ °³¹ß, IP, Ãֽйý±ÔÁ¦ µ¿Çâ¿¡ ´ëÇØ ³íÀÇÇϸç, ¾Æ½Ã¾Æ¸¦ ºñ·ÔÇÑ °¢±¹ÀÇ »ç·Ê¿¬±¸ ¹ßÇ¥°¡ ¿¹Á¤µÇ¾î ÀÖ½À´Ï´Ù.
Cell Line Development and Engineering Asia´Â Áß±¹ ¹× ¾Æ½Ã¾ÆÀÇ »ý¹°Á¦Á¦¿Í ¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ß¿¡ ÃÊÁ¡À» ¸ÂÃâ ¿¹Á¤À̸ç, Á¦4ȸ Antibodies and Vaccines Conference(¾Æ½Ã¾Æ Ç×ü ÄÁÆÛ·±½º 2012)¿Í °øµ¿À¸·Î °³Ãֵ˴ϴÙ.
| È®Á¤µÈ ¿¬»ç |
- Prof. Michael Betenbaugh, Professor and former Chair of Department, Chemical and Biomolecular Engineering, Johns Hopkins University, USA (Academic Keynote)
- Jianguo Yang, Principal Scientist, Genzyme / Sanofi Aventis, USA (Industry Keynote)
- Lin Zhang, Associate Research Fellow, Pfizer, USA
- Zhiwei Song, Research Scientist, BTI A*Star, Singapore
- Cheng Liu, Chief Executive Officer, Eureka Therapeutics, USA
- Steven Lee, Global Head of Biologics, Luye Pharmaceuticals, Singapore
- Dr. Ralf Schumacher, Head Biologics Research, Roche Diagnostics, Germany
- Lee Chichang, Executive Director, Simcere Pharmaceuticals, China
- Wiedong Jiang, CSO and Vice President, Henlix Biopharmaceuticals, USA
- Rustom Mody , Executive Vice President, Intas Biopharmaceuticals, India
- Feng Gao, Chief Operating Officer, AutekBio (Beijing), China
- Brian Salmons , Chief Executive Officer, SG Austria, Singapore
- Yang Yuan Sheng, Research Scientist, BTI, A*Star, Singapore
- Shun Luo, President, JS Biosciences, China
- Emmanuel Guerevitz, Chief Executive Officer, Amagino Biotechnology, Israel
|
| Âü°¡¸¦ ±ÇÀ¯ÇÏ´Â 5°¡Áö ÀÌÀ¯ |
- ¼¼Æ÷ÁÖ °³¹ß°ú ¿£Áö´Ï¾î¸µ¿¡ ÃÊÁ¡À» ¸ÂÃá ¾Æ½Ã¾Æ ÃÖÃÊ ÄÁÆÛ·±½º·Î, ÇöÀç±îÁö À¯·´ ¹× ¹Ì±¹¿¡¼ °°Àº Çà»ç¸¦ °³ÃÖÇØ ¿Ô½À´Ï´Ù.
- ¼¼Æ÷ÁÖ °³¹ß°ú ¿£Áö´Ï¾î¸µ¿¡ °üÇÑ Àü¹®°¡°¡ Ãֽе¿Çâ°ú »ç·Ê¿¬±¸¸¦ ¹ßÇ¥ÇÕ´Ï´Ù.
- ¹ÙÀÌ¿ÀÀǾàǰ ¾÷°è, ¿¬±¸±â°ü, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷¿¡ ÀÇÇÑ »ç·Ê¿¬±¸¸¦ ´Ù·ç¸ç, ÀÌ¿ë °¡´ÉÇÑ ±â¼ú, Á¦Ç°, °ø±Þ¾÷ü¿¡ ´ëÇÑ Á¤º¸¿Í ºñ¿ë È¿À²ÀÌ ³ôÀº ÇÁ·Î¼¼½º °³¹ß¿¡ ´ëÇØ ³íÀÇÇÕ´Ï´Ù.
- º£½ºÆ® ÇÁ·¢Æ¼½º¸¦ Æ÷ÇÔÇÑ ¼¼Æ÷ÁÖ °³¹ß°ú ¿£Áö´Ï¾î¸µ °ü·Ã À̽´, ¼¼Æ÷ ¹ðÅ·ÀÇ °³¼±, ¼±Á¤ ÇÁ·Î¼¼½º¿Í ÀÌÈÄ ¼¼Æ÷ÁÖ °³¹ßÀÇ ÃÖÀûÈ, IP, ¹ý±ÔÁ¦ °úÁ¦ µî¿¡ ´ëÇÑ ÇÁ·Î±×·¥À» ¸¶·ÃÇÏ¿´½À´Ï´Ù.
- ¼¼°è Àü¹®°¡°¡ ÁøÇàÇÏ´Â ¿öÅ©¼¥À» ¸¶·ÃÇÏ¿´½À´Ï´Ù.
|
´ÙÀ½ Çà»ç¿Í °øµ¿À¸·Î °³Ãֵ˴ϴÙ. |

|